More Stories

Heart Failure May 21, 2026

Inflammation’s Prevalence and Role in Heart Failure May 21, 2026

Heart failure inflammation might actually be an underrecognized therapeutic target, after results from the POSEIDON registry analysis found that systemic inflammation is present in nearly half of heart failure patients, regardless of ejection fraction.

Structural Heart May 18, 2026

Cardiac Wire’s State of The Transcatheter Valve May 18, 2026

It might feel like a transcatheter alphabet soup out there with all of the valve interventions that have come out in the last few years, but Cardiac Wire is here to help make sense of it all.

Structural Heart May 14, 2026

The Young TAVR Trend is Stabilizing May 14, 2026

Despite a TAVR popularity surge in recent years, a Vizient registry analysis suggests the procedure’s prevalence has stabilized in patients under 65, but there’s still significant debate on whether the young patient TAVR rate is appropriate.

Cardiovascular Disease May 11, 2026

BP Lowering Still Decreases CVD Risk Even in CKD May 11, 2026

Data from a new Lancet study suggests that patients with chronic kidney disease (CKD) might get similar cardiovascular protection from blood pressure drugs as the general population, giving physicians some certainty about how to approach BP in these patients.

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.

Cardiovascular Disease May 4, 2026

The True Cause of Sudden Cardiac Death May 4, 2026

It’s not often that a pair of studies completely challenges our assumptions in cardiology, but new data presented at HRS 2026 suggests myocardial infarction might not be […]

Get twice-weekly insights on the biggest stories shaping cardiology.